Valneva’s inactivated COVID-19 vaccine
Specialty vaccine company Valneva has developed a whole virus, inactivated, adjuvanted vaccine against COVID-19. It was developed and approved in Europe (conditional approval in the United Kingdom / standard approval in the European Union).
Valneva initiated additional clinical trials to potentially support future approval in further age groups and as a booster.
Read more here: https://valneva.com/research-development/covid-19-vla2001/